More than 65 per cent of the company’s revenues comes from exports, a share that could go up further post Lincoln Pharma's foray into regulated markets.
With presence in more than 60 countries, the company has reported export sales of Rs 174.7 crore for the nine months ended December 2019 and expect the same to cross Rs 225 crore in FY20. However, with the company expanding portfolio in lifestyle and chronic, it is targeting sales of Rs 500 crore in the next 2-3 years, said Patel.
“Going forward, we are building a strong portfolio in lifestyle and chronic segment, especially in women health care and dermatology, to complement our strong presence in acute segment,” said Patel, adding that the company was also planning to apply for a global patent for this novel solution.
Meanwhile, the company recently approved amalgamation of Lincoln Parenteral (subsidiary) with Lincoln Pharmaceuticals.
The restructuring aims to bring synergies for both companies.